Side-by-side comparison of AI visibility scores, market position, and capabilities
Stamford CT technology research and advisory (NYSE: IT) ~$6.8B FY2024 revenue (+9%); Magic Quadrant brand standard, 80%+ recurring Research revenue, AI advisory demand surge competing with Forrester and IDC.
Gartner, Inc. is a Stamford, Connecticut-based technology research and advisory company — publicly traded on the New York Stock Exchange (NYSE: IT) as an S&P 500 Information Technology component — providing objective research, expert guidance, and practitioner tools to technology and business leaders through subscription-based Research (analyst reports, Magic Quadrants, Hype Cycles, peer benchmarking), Conferences (IT Summit, Data & Analytics Summit, Security & Risk Management Summit), and Consulting (custom strategy and benchmarking for enterprise IT organizations) through approximately 20,000 employees serving 15,000+ enterprise client organizations in 100+ countries. In fiscal year 2024, Gartner reported revenues of approximately $6.8 billion (+9% year-over-year) with strong Research segment growth as enterprise technology buyers increased advisory spending to navigate the AI technology landscape, cybersecurity threat complexity, and cloud infrastructure optimization — Gartner's subscription research model (subscription contracts with CIO, CISO, CFO, and HR executive audiences) generates 80%+ recurring revenue with contract value retention rates above 105% (net revenue retention — the average contract grows year-over-year through price increases and seat expansions). CEO Gene Hall has led Gartner's transformation from a pure research analyst firm into a comprehensive executive advisory platform: Gartner's peer benchmarking databases (CIO benchmarking, IT spending by industry sector, technology vendor comparison data), decision support tools (Gartner Peer Insights verified vendor reviews, BuySmart vendor selection wizard), and executive networking programs (CISO Circle, CFO Circle roundtables) create multiple product lines layered on top of the foundational analyst research subscription.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.